Skip to main content

Table 3 Summary of published reports describing pediatric patients with JIA receiving influenza vaccine

From: Immunogenicity and safety of influenza vaccination in patients with juvenile idiopathic arthritis on biological therapy using the microneutralization assay

Article Vaccination season Vaccine type Methodology antibody response Number of JIA patients Number of controls Number of JIA patients on biological therapy Adverse events (AE) Efficacy (seroprotection) according to group and vaccine type Time post-vaccination
Toplak et al. [18]. 2012
Slovenia
2008/2009 A/(H1N1)pdm, H3N2,B Virus neutralization test 31 14 anti-TNFα
4
Short-term AE:
JIA 35%
Control 36%
JIA
100%H1N1
100% H3N2
84%B
1 month
Pain at injection site:
JIA 32%
Control 21%
anti-TNFα
75%H1N1
75%H3N2
10% B
Malaise and headache:
JIA 3%
Control 14%
No severe AE
Control
100% H1N1
100%H3N2
78%B
Malleson et al. [6]. 1993
Canada
1991/1992-2008/2009 A/(H1N1)pdm, H3N2,B HAI 26 13 0 Soreness and redness at injection site:
JIA 69% and 15%
Control 69% and 8%
JIA
100% H1N1
97% H3N2
97% B
4 - 6 week
Fever and feeling unwell:
JIA 19% and 46% Control 8% and 26%
No severe AE
Control
90% H1N1
90% H3N2
90% B
Dell’ Era et al. [25]. 2012
Italy
2010/2011-2008/2009 A/(H1N1)pdm, H3N2,B HAI 60 30 Etanercept
30
Local AE:
JIA with DMARD 43.3%
JIA with Etanercept 36.7%
Control 40%
Systemic AE:
JIA with DMARD 30%
JIA with Etanercept 26.7% Control 26.7%
Severe AE:
JIA with DMARD 3.3%
JIA with Etanercept 3.3%
JIA with DMARD
100% H1N1
100% H3N2
83.3% B
JIA with Etanercept
100% H1N1
100% H3N2
30% B
Control
100% H1N1
100% H3N2
93,3% B
1 month
Aikawa et al. [26]. 2013
Brazil
2009 A/(H1N1)pdm HAI 95 91 anti-TNFα
16
Local pain:
JIA 21.1%
Control 23.1%
JIA
88.4% H1N1
anti-TNFα
100% H1N1
Control
95.6% H1N1
3 weeks
No severe AE
Shinoki et al. [9]. 2012
Japan
2007/2008 A/(H1N1)pdm, H3N2,B HAI 27 17 Tocilizumab
27
Local AE:
JIA14.8%
Control 0%
JIA
88.9% H1N1
85.2% H3N2
40.7% B
4 -7 weeks
No severe AE Control
76.5% H1N1
100% H3N2
35.3% B
Miraglia et al. [5]. 2011
Brazil
2009 A/(H1N1)pdm HAI 83 - Not specified 1.3% redness, 20% malaise JIA JIA
85.5% H1N1
3 weeks
No severe AE
Carvalho et al. [8]. 2013
Brazil
2008
A/(H1N1)pdm, H3N2,B
HAI 44 10 anti-TNFα
5
Local pain
JIA 13.6%
Control 10%
Other local change
JIA4.5%
Control 10%
JIA
100% H1N1
93% H3N2
95% B
Anti TNFα
60% H1N1
100% H3N2
80% B
Control
100% H1N1
80% H3N2
100 B
30-40 days
  1. HAI hemagglutination inhibition, DMARDS disease-modifying anti-rheumatic drugs. Severe AE: defined as patients requiring hospitalization or iv treatment